Opus Genetics, Inc. (IRD) research
Opus Genetics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $4.83
- As of
Opus Genetics, Inc. (IRD): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-11.
As of . Source: SEC EDGAR filings for IRD. Method and limitations.
Share the IRD intelligence card
See IRD live in the terminal
Track IRD's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live IRD terminal, freeActive signals for IRD
- highCONSENSUS_BUY
3 tracked funds increased IRD this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased IRD this 2026Q2, institutional consensus
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in IRD
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +479% to IRD (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +134% to IRD (2026Q2)
FREE, NO ACCOUNT
Every signal on IRD, as it fires
You are seeing 5 of 20 signals recorded on IRD since 2026-05-30.
The five above landed across 2 days. The other 15 were recorded on 3 other days. 11 of the 20 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IRD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 67577R102 · 2026Q2 | $9.5M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 67577R102 · 2026Q2 | $2.7M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 67577R102 · 2026Q2 | $1M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 67577R102 · 2026Q2 | $78K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IRD
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IRD mentioned in Kresmion daily briefs
IRD against its peers
IRD's operating margin of -271.9% ranks in the 50th percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | IRD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 14.2M USD | 38.2M USD | 43 | 14 |
| Operating margin | -271.9% | -266.7% | 50 | 12 |
| Net margin | -349.3% | -247.7% | 42 | 12 |
| Return on equity | -323.1% | -78.4% | 12 | 20 |
Peers (23): EDIT, CABA, ZURA, RLMD, PRTA, ARTV, ARCT, CCCC, SPRY, TTRX, INDP, GALT, LRMR, PROK, PRLD, BNTC, FENC, BBOT, AGEN, ENTX, PBYI, MYGN, RCKT. Left out: PRTC (period gap), VOGX (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (IRD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more IRD signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to IRDand get the insider, 13F, options, and confluence read in one view.